Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

9478	Companies
185489	Keywords
117869	Articles
99348	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 05/19/2025 at 16:42, 6 months 16 days ago

Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research

Crofelemer FDA Approval BUY Rating Jaguar Health Growth Potential
PRESS RELEASE

published on 05/19/2025 at 16:37, 6 months 16 days ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Jaguar Health Inc, recommending a Buy with USD 60.00 price target. Jaguar focuses on plant-based medicines for GI health challenges, with crofelemer as flagship product

Jaguar Health Inc First Berlin Equity Research BUY Rating Plant-based Medicines GI Health Challenges
BRIEF

published on 05/15/2025 at 20:35, 6 months 20 days ago

Jaguar Health Reports Decreased Revenue in Q1 2025

Revenue Decline Prescription Products FDA Meeting Q1 2025 Financials Mytesi Growth
PRESS RELEASE

published on 05/15/2025 at 20:30, 6 months 20 days ago

Jaguar Health Reports First Quarter 2025 Financials
Jaguar Health, Inc. reports Q1 2025 financial results with revenue decrease, Mytesi prescription volume changes, and promising POC results for rare diseases. FDA meeting on Phase 3 trial for breast cancer subgroup

Financial Results Jaguar Health Q1 2025 Mytesi Prescription POC Results
BRIEF

published on 05/14/2025 at 15:05, 6 months 22 days ago

Jaguar Health Schedules Investor Webcast for Q1 2025 Financials

Crofelemer Pharmaceuticals Investor Webcast Jaguar Health Q1 2025 Financials
PRESS RELEASE

published on 05/14/2025 at 15:00, 6 months 22 days ago

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
Jaguar Health, Inc. to file Q1 2025 Earnings Report on May 15, 2025 and conduct investor webcast. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress

Pharmaceuticals Gastrointestinal Distress Earnings Report Investor Webcast Jaguar Health
BRIEF

published on 05/08/2025 at 15:35, 6 months 28 days ago

Jaguar Health Highlights Pet Cancer Awareness with Its Cancer Care Initiatives

Jaguar Health Chemotherapy Canalevia®-CA1 Pet Cancer Cancer Awareness
PRESS RELEASE

published on 05/08/2025 at 15:30, 6 months 28 days ago

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Jaguar Health, Inc. celebrates FDA conditional approval of Canalevia®-CA1 prescription drug for chemotherapy-induced diarrhea in dogs, highlighting National Pet Cancer Awareness Month and supportive cancer care initiatives

FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea National Pet Cancer Awareness Month
BRIEF

published on 05/07/2025 at 15:20, 6 months 29 days ago

Jaguar Health Highlights Key 2025 Developments for Crofelemer

Crofelemer FDA Approval Cancer Therapy Rare Diseases 2025 Catalysts
PRESS RELEASE

published on 05/07/2025 at 15:15, 6 months 29 days ago

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Jaguar Health's crofelemer, the only oral drug approved under FDA's Botanical Guidance, shows promising results in rare disease and cancer therapy-related diarrhea programs. Expected Q2-Q4 2025 catalysts discussed

FDA Crofelemer Jaguar Health Catalysts Oral Drug

Accesswire

Published on 12/05/2025 at 16:00, 25 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 40 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 50 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 1 hour ago

Usha Resources Provides Corporate Updates
Published on 12/05/2025 at 15:00, 1 hour 25 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 16:10, 15 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 25 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 25 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 16:00, 25 minutes ago

Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 15:47, 37 minutes ago

Form 8.3 - The Vanguard Group, Inc.: NCC Group plc

Les Echos

Published on 12/05/2025 at 15:10, 1 hour 14 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 7 hours 40 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 22 hours 25 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 22 hours 40 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 22 hours 41 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution

View all LES ECHOS COMFI WIRE